Sam Altman and Partner Launch Startup for Gene Editing in Babies

OpenAI’s Sam Altman and his husband are backing a bold new startup aiming to develop gene-editing technologies for infants. The company’s mission is both ambitious and controversial—combining AI, biotech, and genome editing to potentially prevent inherited diseases at birth. Experts and ethicists weigh in on the opportunities and dangers, while proponents argue it could revolutionize pediatric healthcare. The piece highlights the team’s vision, regulatory landscape, and the fierce debate over the ethics of editing human DNA.